All In Biotech

Drug Trial Radar · NCT07055451

Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIV

A Phase 1b Study to Evaluate the Safety and Pharmacokinetics of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Neonates Exposed to HIV-1

Last checked: Nov 20, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

16

Planned (sponsor's estimate)

Start

Aug 12, 2025

Primary completion

Mar 2028

Study completion Mar 2028

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Jul 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, up to 120 hours
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical study is to learn more about the study drug, Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), safety, tolerability, and pharmacokinetics (how B/F/TAF is absorbed, modified, distributed, and removed from the body of the participants) in neonates exposed to human immunodeficiency virus type 1 (HIV-1). The primary objective of this study is to evaluate the safety and plasma pharmacokinetics (PK) (how B/F/TAF is absorbed, modified, distributed, and removed from the body of the participants) of B/F/TAF tablet for oral suspension (TOS) in full-term neonates exposed to HIV-1 but uninfected.

Conditions

  • HIV-1-infection

Interventions

  • B/F/TAFDrug

    Tablet for oral suspension administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAs) Though Week 8 After Neonate BirthTime frame: First dose date up to 8 Weeks
  2. Percentage of Participants Experiencing Treatment-emergent Laboratory Abnormalities Through Week 8 After Neonate BirthTime frame: First dose date up to 8 Weeks
  3. Pharmacokinetic (PK) parameters for Bictegravir (BIC): AUCinfTime frame: Predose up to 72 hours postdose
  4. PK parameters for BIC: AUClastTime frame: Predose up to 72 hours postdose
  5. PK parameters for BIC: AUC0-24hTime frame: Predose up to 24 hours postdose
  6. PK parameters for BIC: CmaxTime frame: Predose up to 72 hours postdose
  7. PK parameters for BIC: TmaxTime frame: Predose up to 72 hours postdose
  8. PK parameters for BIC: CminTime frame: Predose up to 72 hours postdose
  9. PK parameters for BIC: C24hTime frame: At 24 hours postdose
  10. PK parameters for BIC: t1/2Time frame: Predose up to 72 hours postdose
  11. PK parameters for BIC: Apparent CL/FTime frame: Predose up to 72 hours postdose
  12. PK parameters for BIC: Apparent Vz/FTime frame: Predose up to 72 hours postdose

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • Ronald Reagan UCLA Medical Center (inpatient hospital)

    Los Angeles, California

  • Grady Health System - Ponce de Leon Center

    Atlanta, Georgia

  • St Jude Children's Research Hospital

    Memphis, Tennessee

  • Family Centre for Research with Ubuntu (FAMCRU)

    Cape Town, South Africa

  • Durban International Clinical Research Site, Enhancing Care Foundation

    Durban, South Africa

  • Perinatal HIV Research Unit (PHRU)

    Gauteng, South Africa

  • WITS RHI Shandukani Research Centre

    Johannesburg, South Africa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.